中国肺球囊成形术的安全性和有效性
Balloon pulmonary angioplasty (BPA) is a potential treatment for patients with pulmonary artery stenosis, including non-operable patients with chronic thromboembolic pulmonary hypertension (CTEPH), takayasu arteritis and fibrosis mediastinitis.
The aim of this study was to evaluate the safety and efficacy of BPA in CTEPH and patients not amenable to pulmonary endarterectomy(PEA) or suffered from persistent CTEPH after PEA, , takayasu arteritis and fibrosis mediastinitis.
研究概览
详细说明
This study is a prospective, multi-center, long-term observational project to study the safety and efficacy of BPA. Clinical evaluation, including: functional capacity, 6-minutes walking test, biomarkers, cardiopulmonary exercise test, electrocardiography, echocardiography, haemodynamics, pulmonary angiography and lung scintigraphy was performed before the initiation therapy of BPA, and 3-12 months after last session of BPA.
we also aim to evaluate the value of FAPI in predicting the efficacy and the prognosis of patients with CTEPH who received BPA.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Zhihong Liu, doctor
- 电话号码:8601088396985
- 邮箱:zhihongliufuwai@163.com
学习地点
-
-
-
Beijing、中国、100037
- 招聘中
- center of pulmonary vascular disease, Fuwai hospital
-
接触:
- Zhihong Liu, doctor
- 电话号码:8601088396816
- 邮箱:zhihongliufuwai@163.com
-
首席研究员:
- Zhihong Liu, MD,PhD
-
Beijing、中国、100037
- 招聘中
- Chinese Academy of Medical Sciences Fuwai hospital
-
接触:
- Zhao zhihui, MD
- 电话号码:8615810348817
- 邮箱:1250167892@qq.com
-
接触:
- Yang Tao, MD
- 电话号码:8618610358576
- 邮箱:tsmcyt@163.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Chronic thromboembolic pulmonary hypertension patients admitted in hospital.
描述
Inclusion Criteria:
- diagnosed with CTEPH according to ESC Guidelines (1) Mean PAP ≥ 25mmHg at rest; or if mean PAP < 25mmHg at rest, have exercise limitations from chronic thromboembolic disease (2)Abnormal ventilation perfusion lung scanning (VQ) scan, pulmonary angiogram, computer tomographic pulmonary angiogram, or magnetic resonance pulmonary angiogram confirming chronic thromboembolic disease as recommended by standard guidelines
- Treatment with anticoagulation for ≥ 3 months before diagnosis of CTEPH
- Not amenable to pulmonary endarterectomy
- Willing to provide informed consent
Exclusion Criteria:
- Patients unwilling or unable to provide written consent for participation in the study.
- Impossible to follow up.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events of BPA procedure.
大体时间:From initiation of BPA to 3-12 months after last session
|
Surveillance of complications including: vessel injury, desaturation, cough, mild hemoptysis (<50ml), severe hemoptysis (>50ml), reperfusion pulmonary injury, death. |
From initiation of BPA to 3-12 months after last session
|
|
Change of Pulmonary artery pressure in mmHg caused by series of BPA.
大体时间:From initiation of BPA to 3-12 months after last session
|
Pulmonary artery pressure in mmHg is obtained by right cardiac catheterization. |
From initiation of BPA to 3-12 months after last session
|
|
Change of Pulmonary vascular resistance (PVR) in Wood U caused by series of BPA.
大体时间:From initiation of BPA to 3-12 months after last session
|
Pulmonary vascular resistance (PVR) in Wood U is obtained by right cardiac catheterization. |
From initiation of BPA to 3-12 months after last session
|
|
Change of cardiac index (CI) in L/m^2 caused by series of BPA.
大体时间:From initiation of BPA to 3-12 months after last session
|
Cardiac index (CI) in L/m^2 is obtained by right cardiac catheterization. |
From initiation of BPA to 3-12 months after last session
|
|
Change of World Health Organization (WHO) functional capacity classification caused by series of BPA.
大体时间:From initiation of BPA to 3-12 months after last session
|
World Health Organization is obtained from electronic medical records. |
From initiation of BPA to 3-12 months after last session
|
|
Change of six minutes walk distance in meter caused by series of BPA.
大体时间:From initiation of BPA to 3-12 months after last session
|
World Health Organization is obtained from electronic medical records. |
From initiation of BPA to 3-12 months after last session
|
|
Change of N-terminal B-type natriuretic peptide in pg/ml caused by series of BPA.
大体时间:From initiation of BPA to 3-12 months after last session
|
World Health Organization is obtained from electronic medical records. |
From initiation of BPA to 3-12 months after last session
|
|
Change of Peak VO2/kg in ml/min/kg caused by series of BPA.
大体时间:From initiation of BPA to 3-12 months after last session
|
Peak VO2/kg in ml/min/kg is obtained by cardiopulmonary exercise test. |
From initiation of BPA to 3-12 months after last session
|
|
Change of diffusing capacity for carbon monoxide caused by series of BPA.
大体时间:From initiation of BPA to 3-12 months after last session
|
diffusing capacity for carbon monoxide in % is obtained from pulmonary function test |
From initiation of BPA to 3-12 months after last session
|
|
Change of fibroblast activation protein inhibitor expression after BPA
大体时间:From initiation of BPA to 3-12 months after last session
|
Change of fibroblast activation protein inhibitor expression after BPA |
From initiation of BPA to 3-12 months after last session
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.